ClinicalTrials.gg
CompletedNCT05613959Veress+Updated Nov 14, 2022

Evaluating the Novel Veress Plus Needle

An observational study in Pneumoperitoneum, sponsored by Prof Jean Calleja-Agius. Completed at 1 site in Malta. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-14.

Sponsored by Prof Jean Calleja-Agius · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
18
Ages
18 Years and older
Sex
All
01

Study summary

18 participants (novices, intermediates and experts) performed in total 248 insertions in a systematic way on Thiel embalmed bodies with wide and small bore versions of the conventional VNc (conventional Veress Needle) and the VN+(The Veress Needle plus). Insertion depth was measured by recording the graduations on the needle under direct laparoscopic vision.

Read the detailed description

In total two Thiel embalmed bodies were used over three days. The first body was a 72 year old male with no previous laparotomy or abdominal scars, who had died of myocardial infarction (Length: 170 cm; bodyweight: 70 kg). The 2nd body was a male of 65 years without abdominal scars. The cause of death had been a hospital acquired pneumonia and pulmonary embolism secondary to metastatic pancreatic cancer (length186 cm; bodyweight: 80kg).

An Aesculap laparoscopy tower set up (Aesculap, 3773 Corporate Parkway, Center Valley, 18034 PA, USA) was used with a 10 mm 30 degrees scope, which was inserted through a balloon trocar (Medtronic Netherlands, Larixplein 4, 5616VB Eindhoven, The Netherlands) in the abdomen just below the umbilicus. Intra-abdominal pressure was stabilized using CO2 (Carbon Dioxide) to 4 mm Hg(Mercury). This pressure-level was as low as possible to allow for unambiguous visualization of the insertions but almost equalling normal abdominal pressure. Two different needle types were used, a thin bore needle with a diameter of 2 millimeter (mm) and a length of 145 mm and a wide bore with 2.8 mm diameter and 145 mm length. The study was registered under number FRECMDS-2021-134 of the Ethical Committee of Faculty of Medicine and Surgery of the University of Malta.

Questionnaire The investigators used a questionnaire which consisted of questions about gender, age and previous experience. A 1 to 5 Likert scale was used to score the "life-likeness" of the Thiel embalmed bodies, realism of the procedure, safety the VN+ procedure, and difficulty of using the new needle design.

Protocol After completing the first part of the questionnaire, the participants were instructed and explained how the mechanism works. During the instruction phase, they were allowed to try the needle on a dedicated area, away from the intended research area, until they were able to manage their grip and found their best insertion strategies. To minimize the risk of hitting organs upon entering the abdominal cavity, certain areas are dedicated for VN (Veress Needle) placement such as Palmer's point in the left upper quadrant of the abdomen. In order to use the bodies as efficiently as possible whilst offering a similar experience in terms of abdominal composition to all participants, the whole upper part of the abdomen was used for the insertions, which were done in an alternating fashion (with and without the safety mechanism) for 12 punctures (2x6) from cranial to caudal so a "fresh" part (with no defect or lesion) of abdominal wall was used for each attempt. The participants were with their backs to the video monitor so they were blinded to what was happening inside the abdomen. Insertion of the VN+ was successful when the mechanism fully unlocked. If not, the attempt was noted as an unsuccessful trial, the cause was determined and the insertion data was removed. After the hands- on part, the participants were asked to fill out the last part of the questionnaire with questions about the quality of the bodies and procedures based on their personal experiences and the difficulty of using the VN+ device. It is important to note that the VN+ dislodge action is not influenced by the amount of insertion force but only by the position of the inner stylet.

Data comparison and Statistical analysis Video footage was used by three observers to determine the insertion depth, indicated by the number of markings engraved on the part of the needle surface inside the abdomen. The true insertion depth was calculated in Excel based on the known distance between each marking. After the participants completed the tests, any differences in maximum insertion depth between the VNc and VN+ groups were determined with a Student's t-test (SPSS v16, SPSS, Inc., Chicago, IL). A p-value \< 0.05 was considered a significant difference. The same was done comparing the wide bore with the small bore needles and other variables including the different genders. The potential learning curve was established based on a regression analysis executed on the averaged outcomes per trial including all trial data. The potential influence of wear was established based on a regression analysis conducted on 12 separately executed trials with the wide bore needles. Wear is defined as diminishing sharpness of the bevel of the Veress needle after each attempt. For the regression analysis a p-value \<0.05 was considered significantly different.

02

Conditions studied

  • Pneumoperitoneum

Browse trials for

Keywords

  • Veress Needle
  • Thiel Embalmed Cadavers
  • Laparoscopy
  • Safety mechanism
03

In context

Pneumoperitoneum

134 studies on the registry are indexed under Pneumoperitoneum; 28 are open to participants now.

This study's enrollment of 18 is below the median of 59 across 48 observational studies indexed under Pneumoperitoneum.

Browse Pneumoperitoneum studies →

Lead sponsor

This is the only study on the registry with Prof Jean Calleja-Agius as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Surgical residents, young surgeons, exeprienced surgeons from the University of Malta Mater Dei Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • medical background, healthy

Exclusion criteria

Exclusion Criteria:

  • physically or mentally handicapped
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
18 participants (actual)
Patient registry
No

Groups and cohorts

  • Veress +

    The Veress+ system was used

    Device: Veress +

  • Veress conventional

    The Conventional Veress needle was used

    Device: Conventional Veress

Interventions

  • DeviceVeress +

    The Veress+ safety mechanism was used

  • DeviceConventional Veress

    The Conventional Veress Needle was used

06

What researchers measure

Primary outcomes

  1. depth of insertion

    the depth of insertion of the needle into the abdominal cavity

    Time frame: 20 minutes

07

Study locations

1 site
  • Laboratory for Anatomy
    Valletta, MSD 2080, Malta
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Sep 2021, 8 months.

Of 26 observational studies under Pneumoperitoneum, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2022
First posted
Nov 14, 2022
StartActual
Jan 1, 2021
Primary completionActual
Sep 26, 2021
CompletionActual
Sep 26, 2021
Last update
Nov 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05613959
Lead sponsor
Prof Jean Calleja-Agius
Responsible party
Prof Jean Calleja-Agius (Associate Professor; Head of Department of Anatomy, University of Malta) — Sponsor-investigator
First posted
Nov 14, 2022
Start date
Jan 1, 2021
Primary completion
Sep 26, 2021
Completion
Sep 26, 2021
Last update
Nov 14, 2022

Study contacts

Jean Calleja Agius, MD PhD
study director · University of Malta

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion